Circulating levels of TNFα and TNF receptor superfamily members in lymphoid neoplasia

American Journal of Hematology

Volumn 65, Issue 2, 2000, Pages 105-110

  Metkar, Sunil S ^a   Naresh, K N ^a   Manna, Partha P ^a   Srinivas, V ^a   Advani, S H ^a   Nadkarni, J J ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

CD27; Fas; HD; NHL; TNF ; TNFRI; TNFRII

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ALTERNATIVE RNA SPLICING; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; HUMAN; LIGAND BINDING; LYMPHOID TISSUE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEMBRANE BINDING; MOLECULAR CLONING; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TISSUE DISTRIBUTION;

ADOLESCENT; ADULT; ANTIGENS, CD27; ANTIGENS, CD95; CHILD; CHILD, PRESCHOOL; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; RECEPTORS, TUMOR NECROSIS FACTOR; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033828358     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-8652(200010)65:2<105::AID-AJH3>3.0.CO;2-R     Document Type: Article

References (41)

1. Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas
2. Tumor necrosis factor receptor superfamily members and their ligands
3. FADD/MORTI is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis
4. A death-domain-containing receptor that mediates apoptosis
5. LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing
6. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity
7. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo: Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay
8. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity
9. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor
10. Characterization in vitro of a human tumor necrosis factor-binding protein: A soluble form of a tumor necrosis factor receptor
11. Shedding of tumor necrosis factor receptors by activated human neutrophils
12. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients
13. Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptors
14. A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex
15. Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients
16. The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis
17. B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40
18. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
19. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro
20. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: A member of an emerging family of cytokines with homology to tumor necrosis factor
21. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma study group
22. Lymphotoxin, tumor necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases
23. Cytokine production (IL-1α, IL-1β, and TNFα) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis. Hodgkin's disease and in non-Hodgkin's lymphomas: An immunocytochemical study
24. Production of tumor necrosis factor-α and lymphotoxin by cells of Hodgkin's neoplastic cell lines HDLM-1 and KM-H2
25. Tumor necrosis factor α and lymphotoxin production in Hodgkin's disease
26. Tumor necrosis factor/cachectin and lymphotoxin gene expression in lymph nodes from lymphoma patients
27. In situ expression of IL-1α and TNF-α genes by Reed-Sternberg cells in Hodgkin's disease
28. Tumor necrosis factor receptors in lymphoid tissues and lymphomas: Source and site of action of tumor necrosis factor alpha
29. The significance of serum levels of soluble 60 kDa receptors for tumor necrosis factor in patients with Hodgkin's disease
30. Elevated circulating levels of TNFalpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients
31. Prognostic significance of TNF α and its p55 soluble receptor in malignant lymphomas
32. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients
33. Expression of Fas and Fas Ligand in Hodgkin's Disease
34. Expression and release of CD27 in human B cell malignancies
35. Frequent expression of Fas/Apo-1 in Hodgkin's disease and anaplastic large-cell lymphomas
36. Expression of CD95 antigen and bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease
37. Fas/Apo-1 expression and function on malignant cells of hematologic and nonhematologic origin
38. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias
39. Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: Absence of prognostic corelations
40. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors
41. Soluble factor levels in the initial staging of high-grade non -Hodgkin's lymphomas